Josh Thomas Georgy, Assistant Professor of Medical Oncology, Associate Physician at Christian Medical College Vellore, shared a post on X:

“DESTINY-Breast11: T-DXd followed by THP significantly high pCR vs ddAC-THP in high-risk HER2+ EBC and better safety profile.

Neoadjuvant landscape shifting? Excited to see full efficacy + safety data in the paper.”

Ashish Singh, Professor, Medical Oncology, Christian Medical College Vellore India, added a comment:

“It’s like using a cruise missile for those 65% patients where the enemy can be defeated with a gun.. waiting for DB05 hope it turns out to be the nuke we need for patients at the highest risk of systemic relapse..”

More posts featuring Breast Cancer on OncoDaily.

Josh Thomas Georgy Highlights DESTINY-Breast11 Results in High-Risk HER2+ Early Breast Cancer

“DESTINY-Breast11: T-DXd followed by THP significantly high pCR vs ddAC-THP in high-risk HER2+ EBC and better safety profile.

Neoadjuvant landscape shifting? Excited to see full efficacy + safety data in the paper.”

“It’s like using a cruise missile for those 65% patients where the enemy can be defeated with a gun.. waiting for DB05 hope it turns out to be the nuke we need for patients at the highest risk of systemic relapse..”